GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Hepatitis B
- Interventions
- Procedure: Blood Sampling
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 93
- Registration Number
- NCT02153320
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: UMEC/VIDrug: Placebo
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 498
- Registration Number
- NCT02152605
- Locations
- 🇺🇦
GSK Investigational Site, Kyiv, Ukraine
Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry
Completed
- Conditions
- Influenza
- Interventions
- Other: Data collection
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 507
- Registration Number
- NCT02148211
- Locations
- 🇺🇸
GSK Investigational Site, Wilmington, North Carolina, United States
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Phase 3
Completed
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3503
- Registration Number
- NCT02145468
- Locations
- 🇬🇧
GSK Investigational Site, York, United Kingdom
AUGMENTIN™ in Dental Infections
Phase 4
Completed
- Conditions
- Focal Infection, Dental
- Interventions
- Drug: Amoxicillin/clavulanateDrug: Clindamycin
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 472
- Registration Number
- NCT02141217
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh City, Vietnam
Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants
Phase 3
Completed
- Conditions
- Rotavirus
- Interventions
- Biological: HRV LyophilizedBiological: HRV Liquid
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 451
- Registration Number
- NCT02141204
- Locations
- 🇮🇳
GSK Investigational Site, Vellore, India
Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02141230
Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)
Phase 4
Withdrawn
- Conditions
- Hepatitis BHepatitis A
- Interventions
- Procedure: Blood sampling
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02135666
- Locations
- 🇨🇿
GSK Investigational Site, Hradec Kralove, Czech Republic
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: MepolizumabDrug: SOC
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 339
- Registration Number
- NCT02135692
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
China HVT Safety, PK, PD
Phase 1
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT02135640
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath